The pricing issue of gene therapy is quite interesting. A comparable treatment which is licensed now (Zolgensma, Novartis), has an estimated price tag of $2 million [1].
Interesting indeed. Would you say that this is price is unreasonably high?
If I am reading the following article correctly, the target patient population for Zolgensma experience an average of 4.2 hospitalizations a year with a mean cost of $150K per hospitalization (2012 dollars and rates)
[1] https://www.bloomberg.com/news/articles/2019-04-07/gene-ther...